Cost effective assay choice for rare disease study designs

Desmond D. Campbell, Robert M. Porsch, Stacey S. Cherny, Valeria Capra, Elisa Merello, Patrizia De Marco, Pak C. Sham, Maria Mercê Garcia-Barceló

Research output: Contribution to journalArticle

Abstract

High throughput assays tend to be expensive per subject. Often studies are limited not so much by the number of subjects available as by assay costs, making assay choice a critical issue. We have developed a framework for assay choice that maximises the number of true disease causing mechanisms 'seen', given limited resources. Although straightforward, some of the ramifications of our methodology run counter to received wisdom on study design. We illustrate our methodology with examples, and have built a website allowing calculation of quantities of interest to those designing rare disease studies.

Original languageEnglish
Article number13023
JournalOrphanet Journal of Rare Diseases
Volume10
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Rare Diseases
Costs and Cost Analysis

Keywords

  • High-throughput assay
  • Rare disease
  • Study design
  • WES
  • WGS

ASJC Scopus subject areas

  • Medicine(all)
  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

Campbell, D. D., Porsch, R. M., Cherny, S. S., Capra, V., Merello, E., De Marco, P., ... Garcia-Barceló, M. M. (2015). Cost effective assay choice for rare disease study designs. Orphanet Journal of Rare Diseases, 10(1), [13023]. https://doi.org/10.1186/s13023-015-0226-9

Cost effective assay choice for rare disease study designs. / Campbell, Desmond D.; Porsch, Robert M.; Cherny, Stacey S.; Capra, Valeria; Merello, Elisa; De Marco, Patrizia; Sham, Pak C.; Garcia-Barceló, Maria Mercê.

In: Orphanet Journal of Rare Diseases, Vol. 10, No. 1, 13023, 2015.

Research output: Contribution to journalArticle

Campbell, DD, Porsch, RM, Cherny, SS, Capra, V, Merello, E, De Marco, P, Sham, PC & Garcia-Barceló, MM 2015, 'Cost effective assay choice for rare disease study designs', Orphanet Journal of Rare Diseases, vol. 10, no. 1, 13023. https://doi.org/10.1186/s13023-015-0226-9
Campbell, Desmond D. ; Porsch, Robert M. ; Cherny, Stacey S. ; Capra, Valeria ; Merello, Elisa ; De Marco, Patrizia ; Sham, Pak C. ; Garcia-Barceló, Maria Mercê. / Cost effective assay choice for rare disease study designs. In: Orphanet Journal of Rare Diseases. 2015 ; Vol. 10, No. 1.
@article{1462e1fd6f394106839e159a6d77de18,
title = "Cost effective assay choice for rare disease study designs",
abstract = "High throughput assays tend to be expensive per subject. Often studies are limited not so much by the number of subjects available as by assay costs, making assay choice a critical issue. We have developed a framework for assay choice that maximises the number of true disease causing mechanisms 'seen', given limited resources. Although straightforward, some of the ramifications of our methodology run counter to received wisdom on study design. We illustrate our methodology with examples, and have built a website allowing calculation of quantities of interest to those designing rare disease studies.",
keywords = "High-throughput assay, Rare disease, Study design, WES, WGS",
author = "Campbell, {Desmond D.} and Porsch, {Robert M.} and Cherny, {Stacey S.} and Valeria Capra and Elisa Merello and {De Marco}, Patrizia and Sham, {Pak C.} and Garcia-Barcel{\'o}, {Maria Merc{\^e}}",
year = "2015",
doi = "10.1186/s13023-015-0226-9",
language = "English",
volume = "10",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Cost effective assay choice for rare disease study designs

AU - Campbell, Desmond D.

AU - Porsch, Robert M.

AU - Cherny, Stacey S.

AU - Capra, Valeria

AU - Merello, Elisa

AU - De Marco, Patrizia

AU - Sham, Pak C.

AU - Garcia-Barceló, Maria Mercê

PY - 2015

Y1 - 2015

N2 - High throughput assays tend to be expensive per subject. Often studies are limited not so much by the number of subjects available as by assay costs, making assay choice a critical issue. We have developed a framework for assay choice that maximises the number of true disease causing mechanisms 'seen', given limited resources. Although straightforward, some of the ramifications of our methodology run counter to received wisdom on study design. We illustrate our methodology with examples, and have built a website allowing calculation of quantities of interest to those designing rare disease studies.

AB - High throughput assays tend to be expensive per subject. Often studies are limited not so much by the number of subjects available as by assay costs, making assay choice a critical issue. We have developed a framework for assay choice that maximises the number of true disease causing mechanisms 'seen', given limited resources. Although straightforward, some of the ramifications of our methodology run counter to received wisdom on study design. We illustrate our methodology with examples, and have built a website allowing calculation of quantities of interest to those designing rare disease studies.

KW - High-throughput assay

KW - Rare disease

KW - Study design

KW - WES

KW - WGS

UR - http://www.scopus.com/inward/record.url?scp=84924116533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924116533&partnerID=8YFLogxK

U2 - 10.1186/s13023-015-0226-9

DO - 10.1186/s13023-015-0226-9

M3 - Article

AN - SCOPUS:84924116533

VL - 10

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 13023

ER -